Come meet Visiopharm August 30th - September 3rd in London, UK at the 26th European Congress of Pathology. Learn about our leading image analysis Quantitative Digital Pathology solutions for research and cancer diagnostics; utilizing our...

Exciting news from Visiopharm - their Ki67 diagnostic App has received the CE mark for in-vitro diagnostic use in Europe. The Virtual Double Staining (VDS) Ki67 module for breast is a novel, patented and now CE-marked diagnostic APP intended...

Join Visiopharm for our webinar, “HER2 Protein Expression in Breast Cancer: Membrane Morphology and Accuracy with Regard to Gene Amplification” presented by Michael Grunkin, PhD the CEO and co-founder of Visiopharm. Date:     Monday,...

Hørsholm, Denmark - Visiopharm is pleased to announce the appointment of Benjamin Freiberg, PhD as Director of Sales for the Americas. In his new role Ben will be responsible for sales growth and the expansion of Visiopharm sales team through...

Hørsholm, Denmark -- Today, the Market Development Fund, announced that it will support Visiopharm’s validation of its novel solutions for cancer diagnostics at seven Danish Hospitals and three international Hospitals. Visiopharm’s...

Join Visiopharm for our webinar, “HER2 Protein Expression in Breast Cancer: Membrane Morphology and Accuracy with Regard to Gene Amplification” presented by Michael Grunkin, PhD the CEO and co-founder of Visiopharm. Date:     Monday,...